#IXHL

Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes Incannex (Nasdaq: IXHL) announced an enhanced development pathway for oral OSA candidate IHL-42X after statistically significant Phase 2 RePOSA results and receipt of FDA Fast Track designation. The company will run a Phase 2 crossover dose-optimization study (DReAMzz) testing dronabinol/acetazolamide ratios, then pursue a streamlined Phase 3 master-protocol program to strengthen efficacy data and improve capital efficiency. Incannex expects to begin dosing in DReAMzz in the coming months.

4 days ago

#IXHL Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes

www.stocktitan.net/news/IXHL/incannex-stren...

0 0 0 0

tickerade

@tickerade.bsky.social

2 months ago

#IXHL's AGM on Jan 15 could remove uncertainty & create bullish setup, highlighting progress & pipeline updates.

0 0 0 0

Stock Master

@stockmaster70.bsky.social

3 months ago

📢 Stocks Trending NOW: #M #MRVL #CAPR #IXHL #DLTR #VRAX #RR #CRWD #PMAX #CRM

0 0 0 0

3 months ago

#IXHL Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)

www.stocktitan.net/news/IXHL/incannex-grant...

0 0 0 0

Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement Incannex (Nasdaq: IXHL) announced Nasdaq has granted a 180-calendar-day extension to regain compliance with the minimum bid price rule, giving the company until April 20, 2026 to maintain a closing bid of at least US$1.00 for the required consecutive trading days.Nasdaq said Incannex meets all other continued listing criteria. The company said it may cure the deficiency within the extension period, including by a reverse stock split if needed, and reaffirmed its recent operational progress, noting delivery of two Phase 2 clinical data packages and an "extremely strong cash position."

4 months ago

#IXHL Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

www.stocktitan.net/news/IXHL/incannex-grant...

0 0 0 0

Market Wire News

@marketwirenews.com

5 months ago

NEWS: ( NASDAQ: #IXHL ) IXHL - Historical Earnings Price Analysis

0 0 0 0

Market Wire News

@marketwirenews.com

5 months ago

JUST IN: ( NASDAQ: #IXHL ) IXHL - Historical Price Movements Surrounding Earnings

0 0 0 0

6 months ago

🚀 Exciting times for #IXHL! Trading at $0.6621, it's riding a bullish wave with strong technicals and a $20M buyback boost! 📈 Consider going long with targets at $0.68 & $0.70. Caution advised due to past dilution & market volatility. Dive in with FeetrAI! 💡 #Stocks #Investing

0 0 0 0

6 months ago

🚀 Exciting times for #IXHL! Despite limited data, a $20M share buyback signals management's confidence. Speculative long position: Enter at $0.90, target $1.10-$1.25, stop loss at $0.80. Stay alert for updates—potential upside awaits! 📈 #StockMarket #FeetrAI

0 0 0 0

6 months ago

🚀 Exciting times for #IXHL! With bullish momentum and a positive MACD, this stock is on the move. Consider a long position at $0.75, targeting $0.85-$0.90. But watch out—RSI suggests it's overbought. Stay sharp and manage risks! 📈 #FeetrAI #StockMarket #InvestSmart

0 0 0 0

6 months ago

🚀 Exciting times for #IXHL! With a surge fueled by sleep apnea drug optimism and a $20M buyback, the stock's showing bullish momentum. Consider a short-term long if it stabilizes above $0.87. Target: $0.95-$1.05. Stay alert for news! 📈 #FeetrAI #StockMarket

0 0 0 0

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder Incannex Healthcare (NASDAQ: IXHL) has announced positive results from its Phase 2 clinical trial of PSX-001 (Psi-GAD), a psilocybin-assisted psychotherapy treatment for Generalised Anxiety Disorder (GAD). The randomized, double-blind, placebo-controlled study involving 73 adult participants showed statistically significant improvements across all endpoints.Key findings include a 12.8-point reduction in HAM-A scores compared to 3.6-point reduction in placebo (p44.1% of patients achieving clinical response and 27% reaching full disease remission. The treatment demonstrated strong safety profile with no serious adverse events reported.The company plans to advance to multi-jurisdiction Phase 2 clinical trials and is exploring strategic partnerships to accelerate PSX-001's development.

6 months ago

#IXHL Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

www.stocktitan.net/news/IXHL/incannex-repor...

0 0 0 0

6 months ago

🚀 Exciting times for #IXHL! Bullish momentum with price at $0.7345 above key MAs and high RSI. Volume surge hints at growing interest, fueled by share buybacks and sleep apnea drug buzz. Consider a long position: Entry $0.73, Target $0.78/$0.82, Stop $0.70. Stay sharp! 📈 #FeetrAI

0 0 0 0

Incannex Healthcare Authorizes $20 Million Share Repurchase Program Incannex Healthcare (Nasdaq: IXHL), a clinical-stage biopharmaceutical company, has announced a $20 million share repurchase program. The program allows the company to repurchase its common stock through various methods, including open market purchases and privately negotiated transactions.CEO Joel Latham emphasized that this initiative reflects confidence in their pipeline strength and strategy, suggesting the current market valuation doesn't reflect their clinical program progress. The repurchase program demonstrates Incannex's commitment to enhancing shareholder value while maintaining disciplined capital allocation for their late-stage clinical pipeline advancement.

6 months ago

#IXHL Incannex Healthcare Authorizes $20 Million Share Repurchase Program

www.stocktitan.net/news/IXHL/incannex-healt...

0 0 0 0

Revolutionary Sleep Apnea Drug Shows 83% Improvement in Phase 2 Trial, Patients Report Life-Changing Benefits New sleep apnea treatment achieves unprecedented 83% symptom reduction in clinical trial. Patient interviews reveal dramatic quality of life improvements. See full results.

7 months ago

#IXHL Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

www.stocktitan.net/news/IXHL/incannex-recei...

1 0 0 0

Incannex Reveals $50M Cash Strength and Breakthrough Phase 2 Results: What This Means for Shareholders Incannex announces $50M cash position and limits ATM usage while reporting significant Phase 2 success for IHL-42X therapy. Get full financial and clinical details.

7 months ago

#IXHL Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

www.stocktitan.net/news/IXHL/incannex-confi...

0 0 0 0

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X Incannex Healthcare (NASDAQ:IXHL) has announced positive topline results from its RePOSA Phase 2 clinical trial for IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA). The trial demonstrated significant improvements in key endpoints, with the drug reducing the Apnoea-Hypopnoea Index (AHI) by up to 83% in the high-dose group and 79% in the low-dose group.The study, involving 121 adult participants, showed statistically significant improvements across multiple measures including oxygen desaturation, sleep quality, and patient-reported outcomes. Both dosage groups demonstrated strong efficacy, with 33.3% to 41.2% of patients achieving >30% AHI reduction. The drug exhibited an excellent safety profile with no serious adverse events reported.Following these positive results, Incannex is preparing for an End-of-Phase 2 meeting with the FDA to discuss the path toward Phase 3 trials and potential commercialization. [ "Significant AHI reduction of up to 83% from baseline in high-dose group", "33.3% to 41.2% of patients achieved >30% reduction in AHI across dose groups", "Statistically significant improvements in oxygen desaturation and patient-reported outcomes", "Excellent safety profile with no serious adverse events reported", "Strong potential as first oral pharmaceutical treatment for 900M+ global OSA patients" ]

7 months ago

#IXHL Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

www.stocktitan.net/news/IXHL/incannex-repor...

0 0 0 0

Revolutionary Oral Sleep Apnea Drug Nears Results: Incannex Phase 2 Trial Reaches Final Stage First-in-class oral treatment for 900M sleep apnea patients advances as Incannex locks Phase 2 database. July results to reveal potential breakthrough. Get Details

8 months ago

#IXHL Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

www.stocktitan.net/news/IXHL/incannex-achie...

0 0 0 0